

# Key Figures (IFRS)

MorphoSys Group (in million €, if not stated otherwise)

	12/31/19	12/31/18	12/31/17	12/31/16	12/31/15	12/31/14	12/31/13	12/31/12	12/31/11	12/31/10
<b>RESULTS<sup>1</sup></b>										
Revenues	71.8	76.4	66.8	49.7	106.2	64.0	78.0	51.9	82.1	87.0
Cost of Sales	12.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3
R&D Expenses	108.4	106.4	113.3	94.0	78.7	56.0	49.2	37.7	55.9	46.9
Selling Expenses <sup>2</sup>	22.7	6.4	4.8	2.4	0	0	0	0	0	0
G&A Expenses	36.7	21.9	15.7	13.4	15.1	14.1	18.8	12.1	14.9	23.2
Personnel Expenses (Excluding Stock-Based Compensation)	57.1	39.2	37.1	33.7	32.4	26.7	27.4	24.1	27.7	29.6
Capital Expenditure	3.7	2.5	13.1	2.9	8.8	20.5	5.6	1.8	2.9	13.8
Depreciation of Tangible Assets	2.0	1.8	2.0	1.8	1.5	1.4	1.5	1.7	1.7	2.1
Amortization of Intangible Assets	1.5	1.9	2.1	2.0	1.9	2.7	3.3	3.5	3.8	4.0
EBIT	(107.9)	(59.1)	(67.6)	(59.9)	17.2	(5.9)	9.9	2.5	9.8	13.1
Net Profit/(Loss)	(103.0)	(56.2)	(69.8)	(60.4)	14.9	(3.0)	13.3	1.9	8.2	9.2
Net Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-	6.0	(0.4)	0.0	-
<b>BALANCE SHEET</b>										
Total Assets	496.4	538.8	415.4	463.6	400.1	426.5	447.7	224.3	228.4	209.8
Cash and Financial Assets	357.4	454.7	312.2	359.5	298.4	352.8	390.7	135.7	134.4	108.4
Intangible Assets	44.8	47.4	67.8	67.9	79.6	46.0	35.1	35.0	66.0	69.2
Total Liabilities	101.7	50.4	56.7	48.1	37.3	77.7	95.5	22.3	31.3	23.9
Stockholders' Equity	394.7	488.4	359.0	415.5	362.7	348.8	352.1	202.0	197.1	185.9
Equity Ratio (in %)	80%	91%	86%	90%	91%	82%	79%	90%	86%	89%
<b>MORPHOSYS SHARE</b>										
Number of Shares Issued	31,957,958	31,839,572	29,420,785	29,159,770	26,537,682	26,456,834	26,220,882	23,358,228	23,112,167	22,890,252
Group Earnings/(Loss) per Share, Basic and Diluted (in €)	(3.26)	(1.79)	(2.41)	(2.28)	0.57	(0.12)	0.54	0.08	0.36	0.40
Dividend (in €)	-	-	-	-	-	-	-	-	-	-
Share Price (in €)	126.80	88.95	76.58	48.75	57.65	76.63	55.85	29.30	17.53	18.53
<b>PERSONNEL DATA</b>										
Total Group Employees (Number <sup>3</sup> )	426	329	326	345	365	329	299	421	446	464

<sup>1</sup> Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the AbD Serotec segment, for the years 2013, 2012 and 2011, revenues, income and expenses in connection with the transaction are shown in the line item "Net Profit/(Loss) from Discontinued Operations." All other line items consist of amounts from continuing operations.

<sup>2</sup> In 2018, selling expenses were presented for the first time. In order to provide comparative information for the previous year, the figures for 2017 and 2016 have been adjusted accordingly.

<sup>3</sup> 2010 to 2012 including employees from the discontinued operations of AbD Serotec.